Diabetes drug shows promise for rare Lung-Heart condition
NCT ID NCT05179356
Summary
This study tested whether dapagliflozin, a medication typically used for diabetes, could help people with pulmonary arterial hypertension. Fifty-two patients with stable symptoms took either the drug or a placebo for several months while researchers measured their exercise capacity and heart function. The goal was to see if this existing medication could provide additional benefits for this serious lung and heart condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rigshospitalet
Copenhagen, 2100, Denmark
Conditions
Explore the condition pages connected to this study.